Universiteit
Leiden

The Netherlands

Long-Term Benzodiazepine Use and Salivary Cortisol The Netherlands Study of Depression and Anxiety (NESDA)

Manthey, L.; Giltay, E.J.; Veen, T. van; Neven, A.K.; Vreeburg, S.A.; Penninx, B.W.J.H.; Zitman, F.G.

Citation

Manthey, L., Giltay, E. J., Veen, T. van, Neven, A. K., Vreeburg, S. A., Penninx, B. W. J. H., & Zitman, F. G. (2010). Long-Term Benzodiazepine Use and Salivary Cortisol The Netherlands Study of Depression and Anxiety (NESDA). *Journal Of Clinical Psychopharmacology*, 30(2), 160-168. doi:10.1097/JCP.0b013e3181d41f41

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/117620>

Note: To cite this publication please use the final published version (if applicable).

Long-Term Benzodiazepine Use and Salivary Cortisol

The Netherlands Study of Depression and Anxiety (NESDA)

Leonie Manthey, MSc,* Erik J. Giltay, MD, PhD,* Tineke van Veen, PhD,*
Arie Knuistingh Neven, MD, PhD,† Sophie A. Vreeburg, MD,‡ Brenda W.J.H. Penninx, PhD,*§
and Frans G. Zitman, MD, PhD*

Background: As benzodiazepines (BZDs) have anxiolytic effects, it is expected that they influence the stress system. During short-term treatment, BZD use was found to suppress cortisol levels. However, little research has been done on the effects of long-term BZD administration on the hypothalamic-pituitary-adrenal (HPA) axis.

Methods: The association between long-term BZD use and cortisol levels was investigated in subjects of the Netherlands Study of Depression and Anxiety with a lifetime diagnosis of anxiety or depression ($n = 1531$). The subjects were categorized as “daily BZD users” ($n = 96$), “infrequent BZD users” ($n = 172$), and “nonusers” ($n = 1263$). Possible associations between characteristics of BZD use (dose, duration, and dependence) and salivary cortisol levels were analyzed.

Main Outcome Measure: Subjects provided 7 saliva samples, from which 4 cortisol indicators were calculated: the cortisol awakening response, diurnal slope, evening cortisol, and cortisol suppression after ingestion of 0.5 mg of dexamethasone.

Results: Daily users used BZDs for a median duration of 26.5 months and had a median daily dosage of 6.0 mg as measured in diazepam equivalents. Evening cortisol levels were significantly lower in daily users ($P = 0.004$; effect size: $d = 0.24$) and infrequent users ($P = 0.04$; effect size: $d = 0.12$) compared to nonusers. We did not find significant differences in the cortisol awakening response, diurnal slope, or in the dexamethasone suppression test.

Conclusions: Despite the finding of slightly lower evening cortisol levels in daily and infrequent BZD users compared to nonusers, results indicate that long-term BZD use is not convincingly associated with HPA axis alterations.

Key Words: benzodiazepines, anxiolytics, cortisol, HPA axis, long-term use

Abbreviations: BZD - benzodiazepines, HPA axis - hypothalamic-pituitary-adrenal axis, CAR - cortisol awakening response, DST - dexamethasone suppression test

(*J Clin Psychopharmacol* 2010;30: 160–168)

As benzodiazepines (BZDs) have anxiolytic and sedating effects, it is expected that they influence the stress system. Most studies on the effects of short-term BZD treatment (maximum of 3 months) on the hypothalamic-pituitary-adrenal (HPA) axis in human subjects reported a decrease in cortisol levels,^{1–11} although some studies reported mixed results.^{12,13}

These inconsistencies may be explained by differences in dosages and half-lives of the BZDs used¹³ and by disparities in the time points used in the assessments (only predrug and post-drug measurements,¹³ at certain time intervals,^{6,8,10–12,14} or for a full circadian cycle^{1,2,5}). Differences in patient groups,^{12,13} and measurements of basal versus stress-provoked cortisol levels may also influence the results.^{3,13} In general, the studies measured plasma cortisol levels^{1–3,5,6,9,11,13} or urinary free cortisol as measures of HPA axis activity.⁴ Associations between BZD use and dexamethasone suppression have only been investigated in 1 study and no clear effect of BZD use on dexamethasone suppression was observed.¹⁴ A few studies found that the cortisol decrease in response to BZD treatment was followed by a return to baseline cortisol levels within only a few hours, despite persisting high plasma drug levels,^{15–17} suggesting fast development of tolerance to the stress axis-suppressing effects of BZDs. In contrast, other studies did report significant cortisol reductions in 24-hour, overnight, and daytime means,¹ suggesting that tolerance does not develop as rapidly.

Tolerance to the effects of BZDs as a consequence of chronic use (>3 months) has been extensively discussed in previous studies.^{18,19} In related research on the therapeutic effects of BZDs, several authors reported that tolerance was developed to only the cognitive and psychomotor effects and not to the anxiolytic effects of chronic BZD treatment,¹⁹ whereas others found decreasing anxiolytic efficacy as well when treatment exceeded a few weeks.¹⁸ Most studies on the effects of BZDs on cortisol levels found that cortisol suppression was maintained for up to 3 months of use.^{1,2,4,9,12}

There was only 1 small cross-sectional study investigating long-term BZD use (>3 months).²⁰ The authors found that long-term users have similar baseline cortisol levels as nonusers, indicating that BZDs do not maintain their cortisol-suppressing effects during longer-term use. In contrast, an additional dosage of BZDs (on top of the BZD dosage that long-term users took in the morning) still affected the HPA axis after chronic use. However, comparison groups were small, no measurement of the whole circadian rhythm was conducted, and no dexamethasone challenge test was applied.²⁰

In this paper, we examine the effects of chronic BZD use on various salivary cortisol measures (cortisol awakening response, diurnal slope, evening cortisol level, and suppression after oral dexamethasone administration). In addition, we explore the effects of dosage, duration of use, and level of dependence. The study was carried out on data from 1531 subjects with a lifetime diagnosis of anxiety and/or depression participating in the Netherlands Study of Depression and Anxiety (NESDA).

MATERIALS AND METHODS

Subjects

Subjects participated in the baseline assessment of the NESDA, an 8-year longitudinal cohort study of 2981 respondents aged 18 to 65 years.²¹ Subjects were recruited from the

From the Departments of *Psychiatry, and †Public Health and Primary Care, Leiden University Medical Centre, Leiden, The Netherlands; ‡Department of Psychiatry, VU University Medical Centre, EMGO Institute and Neuroscience Campus Amsterdam, Amsterdam, The Netherlands; and §Department of Psychiatry, University Medical Centre Groningen, Groningen, The Netherlands. Received July 9, 2009; accepted after revision January 13, 2010.

Reprints: Leonie Manthey, MSc, Department of Psychiatry, Leiden University Medical Centre, The Netherlands, PO Box 96002300 RC, Leiden, The Netherlands (e-mail: L.manthey@lumc.nl).

Copyright © 2010 by Lippincott Williams & Wilkins

ISSN: 0271-0749

DOI: 10.1097/JCP.0b013e3181d41f41

community, general practice, and specialized mental health care institutions throughout the Netherlands. Subjects completed a medical examination, an in-person interview, saliva collection, and several questionnaires. The study protocol was approved by the ethical review board of each participating center, and all subjects signed an informed consent at the baseline assessment.

To investigate the associations between BZD use and salivary cortisol indicators, 3 groups were defined: subjects who reported daily BZD use in the month before the baseline interview ("daily BZD users," $n = 176$), subjects who used BZDs on an infrequent basis in the previous month ("infrequent BZD users," $n = 264$) and those reporting no use of BZDs in the last month ("nonusers," $n = 1854$). All subjects reported a current or past diagnosis of a depressive or anxiety disorder (referred to as a lifetime disorder), defined as an anxiety disorder (panic disorder with or without agoraphobia, generalized anxiety disorder, or social phobia) or depressive disorder (dysthymia or major depressive disorder [MDD]) as assessed by the Composite International Diagnostic Interview (WHO version 2.1) which classifies diagnoses according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders IV-TR (American Psychiatric Association, 2001). From these 3 groups, 1664 (72.5%) subjects returned saliva samples. Responders on saliva collection did not differ from nonresponders in sex (67.7% vs 68.3% women; $P = 0.79$) but were older (43.6 ± 12.5 years vs 37.9 ± 11.9 years; $P < 0.001$), more educated (12.2 ± 3.3 years vs 11.5 ± 3.2 years; $P < 0.001$), and less likely to have a lifetime diagnosis of comorbid disorder (55.5% vs 64.0%; $P < 0.001$). Furthermore, responders had marginally significantly lower rates of BZD use (18.2% vs 21.7%; $P = 0.06$). Of the responders, 1658 provided sufficient cortisol samples of high quality from which at least 1 usable salivary cortisol indicator (cortisol awakening response [CAR], diurnal slope, evening cortisol, or dexamethasone suppression test [DST]; see later section) could be calculated.

Because of known associations with cortisol or use of BZDs for conditions other than anxiety or depression, pregnant or breastfeeding women ($n = 10$), subjects using corticosteroids ($n = 104$), and patients with epilepsy ($n = 13$) were excluded, leaving a final sample of 1531 subjects (1263 nonusers, 172 infrequent BZD users, and 96 daily BZD users).

Measures

Benzodiazepine Use

Four indicators of BZD use were investigated: type of BZD, daily BZD dose, duration of BZD use, and BZD dependence severity. BZD use during the month before baseline interview was registered by observation of drug containers brought to the interview (73.4%) or self-report (26.6%). Daily and infrequent BZD users reported the type and dosage of BZD taken on an average day of use. Frequency of use for infrequent users was taken into account when calculating the average daily dose. The daily BZD dose was computed according to the coding system of the Anatomical Therapeutic Code (ATC) and defined daily dose (DDD) system.²² The mean daily dose was calculated by dividing individual daily doses (in milligrams) of BZDs by the DDD for the particular BZD. Benzodiazepines were classified as ATC-coded groups N05BA, N05CD, and N03AE01. The non-BZD hypnotics zopiclone and zolpidem (ATC code N05CF) were also included. Similar to BZDs, these hypnotics act on the central omega 1 gamma aminobutyric acid receptor. For patients using BZDs other than diazepam, an equivalent daily dose was calculated with conversion tables,^{23,24} and 10 mg of diazepam was regarded equivalent to 1 mg of alprazolam, 10 mg of bro-

zepam, 0.25 mg of brotizolam, 20 mg of clobazam, 20 mg of chlordiazepoxide, 13.3 mg of clorazepate, 8 mg of clonazepam, 30 mg of flurazepam, 1 mg of loprazolam, 2 mg of lorazepam, 1 mg of lormetazepam, 7.5 mg of midazolam, 10 mg of nitrazepam, 33 mg of oxazepam, 20 mg of prazepam, 20 mg of temazepam, 20 mg of zolpidem, and 13 mg of zopiclone. Dosages were summed when more than 1 BZD was used. The duration of BZD use was reported in months. Benzodiazepine users completed the Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ), a 15-item self-report questionnaire, as a measure of dependence severity. Each item was rated on a 5-point scale. Three dependence dimensions were derived: (1) awareness of problematic use, (2) preoccupation with the availability of benzodiazepines, and (3) lack of compliance with the therapeutic regimen.²⁵ The Bendep-SRQ has good scalability, reliability, and validity in general practice patients²⁶ and in psychiatric outpatients.²⁷

Salivary Cortisol

The respondents were asked to collect saliva samples at home on a regular, preferably working day shortly after the baseline interview by using Salivettes (Sarstedt AG and Co, Nürmbrecht, Germany).²⁸ The median time between the interview and saliva sampling was 9 days (25th–75th percentile: 4–22). Eating, smoking, drinking tea or coffee, or brushing teeth was prohibited within 15 minutes of sampling. Saliva was measured at 7 time points (Ts): upon awakening (T1), 30 minutes (T2), 45 minutes (T3), and 60 minutes (T4) after awakening and in the evening at 10 PM (T5) and 11 PM (T6). Immediately after saliva sampling at T6, the cortisol suppression test was carried out by oral administration of a 0.5-mg dexamethasone pill and assessed by cortisol sampling the next morning directly after awakening (T7). All samples were refrigerated and returned by mail. During laboratory analysis, Salivettes were centrifuged at 2000g for 10 minutes, aliquoted, and stored at -80°C . Competitive electrochemiluminescence immunoassay (E170, Roche, Basel, Switzerland) was used to measure cortisol levels at a functional detection limit of 2.0 nmol/L.²⁹ Intra-assay and interassay variability coefficients in the measuring range were less than 10%. Assays were repeated if cortisol levels were very high (>80 nmol/L) or very low (<1 nmol/L) ($n = 128$). All very high samples remained high in the second measurement, and the mean of the 2 measured values was used in further analyses. In 80% of the very low samples, the repeated cortisol value was within the reference range and was used for analysis. In cases where the second measurement was also very low, the mean of the samples was used. Data cleaning was performed by excluding cortisol values more than 2 SDs above the mean.²⁸

Four cortisol measures were derived: the CAR, diurnal slope, evening cortisol, and cortisol suppression on the DST.²⁸

Cortisol Awakening Response (CAR)

The CAR was calculated from 4 sampling points: T1, T2, T3, and T4. In our study, it was calculated by analysis of T1 to T4 with linear mixed models (LMM) and 2 aggregate indicators: area under the curve with respect to the ground (AUCg) and with respect to the increase (AUCi) according to Pruessner's formulas.³⁰ The AUCg is an estimate of the total cortisol secretion and predicts mean cortisol levels throughout the day, and the AUCi is a measure of the dynamics of the CAR, related to the sensitivity of the system and emphasizing changes over time.^{28,30} For the AUC analyses, a minimum of 3 samples were required. For those with 1 missing cortisol value ($n = 84$), the fourth was imputed using linear regression analyses with

information on the other available 3 cortisol values, sex, age, awakening time, and smoking status.

Diurnal Slope and Evening Cortisol

As cortisol levels at 10 PM (T5) and 11 PM (T6) were correlated ($r = 0.73$, $P < 0.01$), evening cortisol was defined as the average of the 2 values (T5 and T6) or by one of the 2 if only one was available. Diurnal slope was calculated by subtracting the evening cortisol level (as calculated earlier) from the cortisol

level at T1 and dividing it by the time in hours between the 2 samples, resulting in the change over time of cortisol throughout the day, calculated per hour.^{28,31}

Dexamethasone Suppression Test (DST)

In addition to the cortisol level at awakening after dexamethasone ingestion (T7), a cortisol suppression ratio was calculated by dividing the cortisol value at awakening on day 1 (T1) by the post-dexamethasone cortisol value at awakening

TABLE 1. Characteristics of Study Groups

	N	Nonusers n = 1263	Infrequent Users n = 172	Daily Users n = 96	P
Sociodemographics					
Sex, % female	1531	67.2	71.5	58.3	0.09
Age, yrs	1531	42.5 (41.9–43.2)	46.0 (44.2–47.9)	48.6 (46.2–51.1)	<0.001
Education level, yrs	1531	12.3 (12.1–12.5)	12.0 (11.5–12.5)	11.3 (10.6–11.9)	0.009
North European ancestry, %	1531	95.1	93.0	96.9	0.34
Sampling characteristics					
Time of awakening	1531	7.27 h (7.23–7.31 h)	7.40 h (7.28–7.52 h)	7.39 h (7.24–7.53 h)	0.05
Working on day of sampling, %	1531	63.2	50.6	33.3	<0.001
Sampling on a weekday, %	1531	92.8	86.0	86.5	0.002
Sampling in month with more daylight hours, %	1531	56.4	64.0	47.9	0.03
≤6 hours of sleep, %	1531	27.6	41.3	41.7	<0.001
Health indicators					
Smoking, %	1531	36.1	35.5	40.6	0.65
Physical activity (1000 MET min/wk)	1531	3.7 (3.5–3.9)	3.5 (3.1–4.0)	3.1 (2.5–3.7)	0.13
Psychiatric indicators					
Lifetime diagnosis, %					
MDD only	1531	31.0	23.8	24.0	0.07
Anxiety only	1531	15.4	12.2	9.4	0.18
Comorbid disorder	1531	53.7	64.0	66.7	0.003
Benzodiazepine (BZD) use					
Duration of BZD use, mo.	268	N/A	36.0 (5.0–99.0)	26.5 (5.3–96.0)	0.29
Daily dosage of BZD (diazepam equivalents, mg)*	268	N/A	1.0 (0.2–2.0)	6.0 (3.2–13.9)	<0.001
Type of BZD					
Oxazepam	1531	N/A	48.8	36.5	<0.001
Temazepam	1531	N/A	24.4	14.6	<0.001
Diazepam	1531	N/A	13.4	10.4	<0.001
Alprazolam	1531	N/A	2.3	14.6	<0.001
Others	1531	N/A	19.2	45.8	<0.001
Bendep SRQ					
Highly problematic use	232	N/A	8.0 (6.0–11.0)	10.0 (8.0–12.0)	<0.001
High preoccupation	232	N/A	12.0 (9.0–14.0)	15.0 (13.0–17.0)	<0.001
High lack of compliance	232	N/A	6.0 (5.0–8.0)	8.0 (6.0–10.0)	<0.001
Antidepressant use, %					
SSRI	1525	17.6	29.1	44.8	<0.001
TCA	1530	2.7	5.2	7.3	0.02
Others	1528	6.0	10.5	16.7	<0.001

Means (95% confidence intervals [CI]) are given for age, education, time of awakening, physical activity. Median (interquartile range) is given for duration of BZD use, daily dosage of BZD use, and BENDEP-SRQ, as these values are not normally distributed. Percentages are given for categorical variables. P is derived by analysis of variance (ANOVA) for quantitative, normally distributed variables, Mann-Whitney U test for continuous, non-normally distributed variables, or χ^2 statistics for categorical variables. Significance is inferred at $P < 0.05$.

*Users reported the dosage of BZDs taken on an average day of use. Frequency of use has been taken into account for infrequent users.

BENDEP-SRQ indicates Benzodiazepine Dependence Self-Report Questionnaire; MDD, major depressive disorder; MET, metabolic equivalent of number of calories spent per average minute; N/A, not applicable; SSRI, selective serotonin reuptake inhibitor; T, time point; TCA, tricyclic antidepressant.

TABLE 2. Associations Between Benzodiazepine Use and Various Salivary Cortisol Indicators

Cortisol Characteristics	N	Nonusers n = 1263	Infrequent Users n = 172	Daily Users n = 96	Nonusers vs Daily Users	Nonusers vs Infrequent Users	P
Unadjusted cortisol characteristics							
Cortisol awakening response							
Cortisol T1, at awakening, nmol/L	1517	15.6 (15.3–16.0)	15.8 (14.8–16.8)	15.2 (14.0–16.5)	0.53		0.77
Cortisol T2, + 30 min, nmol/L	1509	19.3 (18.8–19.8)	19.7 (18.4–21.1)	18.3 (16.8–20.1)	0.29		0.54
Cortisol T3, + 45 min, nmol/L	1508	17.9 (17.4–18.4)	18.3 (17.0–19.7)	16.5 (14.9–18.2)	0.12		0.57
Cortisol T4, + 60 min, nmol/L	1511	15.7 (15.3–16.2)	15.3 (14.2–16.5)	14.9 (13.5–16.4)	0.29		0.48
AUCg, nmol/L per hour	1490	18.1 (17.7–18.4)	18.3 (17.2–19.3)	17.2 (16.0–18.6)	0.25		0.73
AUCi, nmol/L per hour	1490	2.5 (2.1–2.9)	2.3 (1.3–3.3)	2.3 (1.0–3.6)	0.75		0.73
Evening cortisol, nmol/L	1525	4.8 (4.7–5.0)	4.6 (4.2–5.0)	4.6 (4.2–5.2)	0.50		0.26
Dexamethasone suppression test							
Cortisol suppression ratio [†]	1452	2.4 (2.3–2.5)	2.4 (2.2–2.6)	2.2 (1.9–2.4)	0.05		0.91
Cortisol T7, after dexamethasone, nmol/L	1476	6.6 (6.4–6.8)	6.6 (6.1–7.1)	7.1 (6.4–7.9)	0.16		0.98
Diurnal slope, nmol/L per hour	1510	0.8 (0.7–0.8)	0.8 (0.8–0.9)	0.8 (0.7–0.9)	0.55		0.06
Adjusted cortisol characteristics*							
Cortisol awakening response							
AUCg, nmol/L per hour	1490	18.1 (17.77–18.4)	18.3 (17.3–19.3)	16.8 (15.6–18.1)	0.09		0.74
AUCi (in nmol/L per hour	1490	2.5 (2.1–2.8)	2.5 (1.5–3.4)	2.5 (1.2–3.8)	0.99		0.99
Evening cortisol, nmol/L	1525	4.9 (4.7–5.0)	4.5 (4.1–4.8)	4.2 (3.8–4.7)	0.004		0.04
Dexamethasone suppression test							
Cortisol suppression ratio [†]	1452	2.4 (2.3–2.4)	2.5 (2.3–2.7)	2.3 (2.1–2.6)	0.71		0.46
Cortisol T7, after dexamethasone, nmol/L per hour	1476	6.6 (6.5–6.8)	6.4 (5.9–6.9)	6.4 (5.8–7.1)	0.46		0.31
Diurnal slope, nmol/L per hour	1510	0.8 (0.7–0.8)	0.8 (0.8–0.9)	0.8 (0.7–0.9)	0.79		0.17

For all cortisol indicators, except for AUCi and diurnal slope, geometric means (95% CIs) are presented based on estimated marginal means calculated by analysis of covariance (ANCOVA). For AUCi, estimated marginal means (95% CIs) are presented. *P* values are calculated by ANCOVA, comparing 2 groups at a time. Significance is inferred at *P* < 0.05.

Nonusers are the reference group.

*Adjusted for sociodemographics (sex, age, education, and North European ancestry), sampling factors (working, weekday, time of awakening, sleep, and month with more day light), comorbidity, antidepressant use (none/SSRI/TCA/other) and health indicators (smoking and physical activity).

[†]Cortisol suppression ratio = salivary cortisol T1/salivary cortisol T7, after 0.5 mg of dexamethasone.

AUCg indicates area under the morning curve with respect to the ground; AUCi, area under the morning curve with respect to the increase.

on day 2 (T7). Lower post-dexamethasone cortisol levels (T7) and higher DST ratios (ie, a larger difference between T1 and T7) indicate a greater cortisol-suppressing effect of dexamethasone.

Covariates

As associations between sociodemographics (sex, age, education, and North European ancestry), sampling factors (awakening time, work status, weekday, season, and sleep duration), and health indicators (smoking, physical activity) on salivary cortisol variables have been described previously,³² these identified determinants were considered as covariates.

Comorbidity of anxiety and depression as well as antidepressant use have been found to be associated with salivary cortisol levels in previous research in this study sample,²⁸ and numbers of antidepressant use and comorbidity differed between BZD groups (Table 1). Therefore, comorbidity and antidepressant use were also included as covariates. Depression and anxiety disorders were established with the Composite International Diagnostic Interview (WHO version 2.1), which classifies diagnoses according to the criteria of the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision* (American Psychiatric Association, 2001). The use of antidepressants in the past month was determined by observation of drug containers brought to the baseline interview. Antidepressants were subdivided into selective serotonin reuptake inhibitors (SSRI, ATC code N06AB), tricyclic antidepressants (TCA, ATC code N06AA), and other antidepressants (monoamine oxidase inhibitors N06AG, nonselective N06AF, and antidepressants classified as N06AX).

Respondents were asked to report the time of awakening and working status on the sampling day. Sampling date information was used to categorize weekday versus weekend day and season categorized in less daylight (October through February) and more daylight (March through September) months. Average sleep duration during the last week was dichotomized as ≤ 6 or > 6 hours/night, and smoking status as current versus non-smoker. Physical activity was assessed using the International Physical Activity Questionnaire and expressed as activity per 1000 MET-minutes (metabolic equivalent of the number of calories spent by a person per average minute) a week.²⁸

Statistical Analyses

Characteristics of study groups were expressed by frequencies, means, or medians and compared using χ^2 statistics (categorical variables), analysis of variance (continuous variables, normally distributed), and the Mann-Whitney *U* test (continuous variables, non-normally distributed). Area under the curve with respect to increase and diurnal slope were normally distributed, which allowed data analysis with nontransformed values. T1-T4, AUCg, evening cortisol, T7, and DST were naturally log transformed because of their positively skewed distributions. Back-transformed values are given in Table 2.

Differences in AUCg, AUCi, diurnal slope, evening cortisol, T7, and DST across groups were analyzed using analysis of covariance (ANCOVA), adjusting for basic sociodemographic variables, sampling factors, health indicators, comorbidity, and antidepressant use. Cohen's *d* (the difference in group means divided by their pooled SD) was calculated as a measure of effect size. Further analysis of the CAR was carried out with random coefficient analysis of the 4 morning cortisol data points by using LMM. This analysis keeps original values on all 4 data points, accommodates for missing data, and takes cor-

relations between repeated measurements within subjects into account.³³

Linear regression analyses were used to assess associations between characteristics of BZD use (ie, duration, dose, and addiction as separate independent variables) and salivary cortisol indicators as continuous dependent variables after full adjustment in daily and infrequent BZD users.

Differences across the 4 most commonly used benzodiazepine types, that is, oxazepam ($n = 115$), diazepam ($n = 33$), alprazolam ($n = 16$), and temazepam ($n = 45$) on salivary cortisol indicators were analyzed in pairwise comparisons using ANCOVA, adjusting for the aforementioned covariates. The other BZDs were not included in these analyses, as group numbers were too small ($n < 15$). Oxazepam was used as the reference group. Statistical significance was inferred at $P < 0.05$. All statistical analyses were conducted using SPSS for Windows, version 16.0 (SPSS, Chicago, Ill).

RESULTS

Characteristics of the 3 BZD user groups are presented in Table 1. Benzodiazepine users were older, less educated, more often diagnosed with a comorbid disorder, and more likely to use antidepressants compared to nonusers. Only 17.9% of subjects were short-term users (≤ 3 months), and the remaining 82.1% were long-term users (> 3 months). The median duration of use was 35.5 months (25th–75th percentile: 5–96). Although the group of short-term users was too small ($n = 48$) to be analyzed separately, exclusion of these subjects did not affect our main results (data not shown). The median daily dosage of BZDs used was 1.0 mg (25th–75th percentile: 0.2–2.0) of diazepam equivalents for infrequent users and 6.0 mg (25th–75th percentile: 3.2–13.9) of diazepam equivalents for daily users. Crude saliva levels (T1-T4 and T7) did not differ between groups (Table 2).

Cortisol Awakening Response

Overall, 71.5% of respondents showed an increase in cortisol in the first hour after awakening, with a mean increase of 6.6 nmol/L (or 53.5%). No significant effects were found for any of the crude CAR analyses (Table 2). Adjusted CAR results showed that daily users and infrequent users did not differ on overall cortisol levels from nonusers, reflected by analysis of AUCg ($P = 0.09$ for daily users vs nonusers and $P = 0.74$ for infrequent users vs nonusers; Table 2) and LMM analysis (daily users vs nonusers, $F_{(1329, 0.097)} = 3.07$, $P = 0.08$; and infrequent users vs nonusers, $F_{(1413, 642)} = 0.11$, $P = 0.74$). A nonsignificant effect on AUCi (daily users vs nonusers, $P = 0.99$; infrequent users vs nonusers, $P = 0.99$; Table 2) and no significant group by time interaction in the LMM analysis (daily users vs nonusers, $F_{(3947, 327)} = 0.49$, $P = 0.69$, and infrequent users vs nonusers, $F_{(4171, 422)} = 0.92$, $P = 0.43$) were found, indicating a similar time course between groups.

Diurnal Slope

No significant effects were found for crude or adjusted diurnal slope analyses (daily users vs nonusers: $P = 0.79$).

Evening Cortisol Level

Unadjusted evening cortisol levels did not differ between groups (Table 2). After adjustment, evening cortisol was significantly lower in daily BZD users ($P = 0.004$; effect size [Cohen's *d*], 0.24) and infrequent users ($P = 0.04$; effect size, 0.12) compared to nonusers. Age and SSRI use were the most important confounders in the fully adjusted model.

TABLE 3. Associations Between Dose and Duration of Benzodiazepine (BZD) Use as Well as Severity of Benzodiazepine Dependence and Various Cortisol Indicators in a Sample of 285 Benzodiazepine Users

Cortisol Indicators—Adjusted*	Characteristics of BZD Use			BZD Dependence (BENDEP-SRQ)					
	Duration of BZD Use		Daily BZD Dose		Problematic Use		Preoccupation		Lack of Compliance
	n	β	P	β	P	β	P	β	P
Cortisol awakening response									
AUCg, nmol/L per hour	261	-0.031	0.64	-0.013	0.84	-0.005	0.95	0.057	0.39
AUCi, nmol/L per hour	261	0.010	0.88	0.048	0.47	-0.054	0.46	0.042	0.55
Evening cortisol									
Evening cortisol, nmol/L	267	-0.097	0.11	-0.046	0.46	0.037	0.58	-0.003	0.96
Dexamethasone suppression test									
Cortisol suppression ratio [†]	249	0.089	0.20	-0.084	0.22	0.112	0.13	0.048	0.50
Cortisol T7, after dexamethasone, nmol/L	254	-0.147	0.03	0.028	0.68	-0.076	0.30	-0.011	0.87
Diurnal slope									
Diurnal slope—adjusted, nmol/L per hour	262	-0.036	0.59	-0.04	0.57	0.034	0.65	0.019	0.78
Duration of BZD use ranges from 1 to 512 months.									
Daily BZD dose is calculated as diazepam equivalents; mean daily doses are given, ranging from 0.05 to 105 mg (in diazepam equivalents).									
AUCg, basal cortisol, cortisol suppression ratio, and cortisol T7 were naturally log transformed before regression analyses. Benzodiazepine nonusers were excluded from the regression analyses.									
*Adjusted for sociodemographics (sex, age, education, and North European ancestry), sampling factors (working, weekday, time of awakening, sleep, and month with more daylight), comorbidity, antidepressant use (none/SSRI/TCA/others), and health indicators (smoking and physical activity).									
[†] Cortisol suppression ratio = salivary cortisol T1/salivary cortisol T7, after oral ingestion of 0.5 mg of dexamethasone.									
β indicates standardized beta coefficient by linear regression analyses.									

Dexamethasone Suppression Test

The unadjusted cortisol suppression ratio was significantly lower in daily users compared to nonusers ($P = 0.05$; effect size, 0.08; Table 2), which indicates increased nonsuppression after dexamethasone ingestion in the daily user group. After adjustment, however, cortisol suppression ratios ($P = 0.71$) and T7 levels ($P = 0.46$) did not differ between groups. Infrequent users also did not differ from nonusers on either of the cortisol indicators ($P = 0.46$ for cortisol suppression ratio and $P = 0.31$ for T7).

Characteristics of BZD Use

Table 3 reports the results of additional analyses on specific associations between salivary cortisol levels and characteristics of BZD use (duration, dose, and severity of BZD dependence as measured by the Bendep-SRQ) among the combined BZD user groups (infrequent and daily). For the duration of use, no effect on any cortisol indicator was found except for a weak negative association with adjusted T7 cortisol levels after dexamethasone ingestion ($\beta = -0.15$, $P = 0.03$), indicating that a longer duration of BZD use was associated with a somewhat lower cortisol level after dexamethasone ingestion, that is, stronger suppression. The daily BZD dose and the 3 subscales of the Bendep-SRQ (problematic use, preoccupation, and lack of compliance) were not associated with any salivary cortisol indicator.

Pairwise comparisons of the most common BZD types showed that the temazepam group did not differ from the oxazepam group on any of the cortisol indicators. However, the diazepam group had lower diurnal slope levels ($P = 0.01$) and a decreased dexamethasone suppression ratio ($P = 0.01$) compared to oxazepam users. The alprazolam group had a lower AUCg than the oxazepam group ($P = 0.007$; data not shown).

DISCUSSION

In this study, the relationship between BZD use and various salivary cortisol measures was studied in NESDA subjects with a lifetime diagnosis of depression and/or anxiety. With the exception of slightly lower evening cortisol levels in daily and infrequent BZD users compared with nonusers, the user groups did not differ on any cortisol indicators after adjustment for covariates. Dose, frequency of use, and dependence were not associated with salivary cortisol levels except of a correlation of longer duration of use with stronger cortisol suppression after dexamethasone ingestion. As effect sizes found were small, the clinical relevance of the statistically significant findings is limited. Further, in the light of the number of tests conducted, multiple testing may have caused a type 1 error for evening cortisol in BZD users.

An explanation for the lack of consistent associations could be that BZDs inhibit the HPA axis during short-term use and that tolerance to the cortisol-suppressing effect of BZDs develops after long-term BZD treatment. Correspondingly, intervention studies that found lower cortisol levels in response to BZD administration mainly looked at short-term effects during a period ranging from 1 day to 1 month,^{3,5,6,9,13,34–37} except for a few studies with a duration of 2–3 months.^{1,2,4} In contrast, long-term users were found to have similar baseline cortisol levels as nonusers, also indicating that BZDs do not maintain their cortisol-suppressing effects in long-term use.²⁰ As our study mainly consists of long-term users (3-year median duration of use), the lack of association between BZD use and baseline cortisol levels agrees with results from the latter study.²⁰

Although tolerance is likely to develop during long-term use, an additional dosage of BZDs (on top of a regular daily dosage) still induces HPA axis inhibition. Indeed, Cowley et al²⁰ found that long-term users showed similar decreases in plasma cortisol after an extra dosage of BZDs as treatment-naïve patients. In related research on the therapeutic effects of BZDs, an increased dosage of BZDs was found to increase anxiolytic effects even after more than 10 years of daily use.³⁸

Along with the hypothesis of tolerance development to the cortisol-suppressing effects of long-term BZD use, there are several alternative explanations that may account for discrepancies in the findings. First, BZD users may have had enhanced HPA axis activity before the start of BZD treatment, which was subsequently normalized by long-term BZD treatment. Indeed, a significantly higher percentage of daily users compared to nonusers had a comorbid disorder, which has been found to be associated with increased cortisol levels in this study population.²⁸ Second, it might be that the joint investigation of a number of different types of BZDs with possibly opposing effects on the HPA axis has covered effects on cortisol levels.³⁹ We found lower diurnal slope levels and a decreased dexamethasone suppression ratio in the diazepam group and a lower AUCg in the alprazolam group compared to the oxazepam group, suggesting some evidence for possibly opposing effects of different BZDs. This corresponds to a former study that reported BZDs to have either a stimulating or an inhibiting effect on the HPA axis conditional on the alpha subunit of the GABA receptor modulated by the drugs.³⁹ However, as comparison groups were small in NESDA, results have to be replicated in future research. Third, stronger effects on cortisol levels may be due to higher dosages. In intervention studies, higher average dosages were used than in the current study (ie, 12 mg of diazepam equivalents in intervention studies vs 6 mg in NESDA). Another explanation for basal cortisol being the only cortisol measurement differing significantly between BZD user groups might be that hippocampal mineralocorticoid receptors (MRs) are more affected by central-acting BZDs than glucocorticoid receptors (GRs). Because MRs are more occupied at intermediate cortisol concentrations whereas GRs are not,⁴⁰ basal evening cortisol might be a probe of MR activity.⁴¹ However, because research on GR, MR, and BZDs is still limited, this assumption deserves further investigation in future research.

Our study has some limitations. A cross-sectional analysis was done, which precludes causal inferences or differentiation between the potential explanations of the lack of group differences in salivary cortisol. Because we had to rely on subjects' self-report on BZD intake, we cannot be completely sure whether subjects were actually using the medications as prescribed and as they themselves indicated. Noncompliance with instructions of saliva collection due to the ambulatory setting could have resulted in measurement error. In addition, because time of drug intake was not recorded, acute effects of BZD use could not be assessed. Despite these limitations, our study had many strong aspects, including a large sample size with clearly distinct BZD groups primarily composed of long-term users, the inclusion of multiple cortisol measures indicative of different aspects of HPA axis activity, the investigation of various characteristics of use and the adjustment for various potential confounders.

In conclusion, we found no consistent associations between BZD use and salivary cortisol indicators within a sample composed primarily of long-term users. This finding is in line with the hypothesis that the HPA axis develops tolerance to the cortisol-suppressing effect of BZDs during chronic BZD use.

ACKNOWLEDGMENTS

The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1002) and is supported by participating universities and mental health care organizations (VU University Medical Center, GGZ in Geest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific Institute for Quality of Health Care (IQ Healthcare), Netherlands Institute for Health Services Research (NIVEL), and Netherlands Institute of Mental Health and Addiction (Trimbos).

The authors thank Caroline Leeds for her assistance throughout the editing process.

AUTHOR DISCLOSURE INFORMATION

The authors declare no conflict of interest.

REFERENCES

- Abelson JL, Curtis GC, Cameron OG. Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. *J Psychiatr Res.* 1996;30:79–93.
- Curtis GC, Abelson JL, Gold PW. Adrenocorticotrophic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. *Biol Psychiatry.* 1997;41:76–85.
- Fries E, Hellhammer DH, Hellhammer J. Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. *Psychoneuroendocrinology.* 2006;31:1278–1288.
- Lopez AL, Kathol RG, Noyes R. Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. *Psychoneuroendocrinology.* 1990;15:23–28.
- Mcintyre IM, Norman TR, Burrows GD, et al. Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans. *Chronobiol Int.* 1993;10:205–213.
- Osman OT, Hsiao JK, Potter WZ. Dose dependent effects of intravenous alprazolam on neuroendocrine, biochemical, cardiovascular, and behavioral parameters in humans. *Psychopharmacology (Berl).* 1993;111:295–300.
- Burrows GD, Norman TR, Judd FK, et al. Short-acting versus long-acting benzodiazepines—discontinuation effects in panic disorders. *J Psychiatr Res.* 1990;24:65–72.
- Christensen P, Gram LF, Kraghsoresen P, et al. Afternoon cortisol levels before (spontaneous) and after suppression with dexamethasone or oxazepam in depressed-patients. *J Affect Disord.* 1986;10:171–176.
- Pomara N, Willoughby LM, Sittits JJ, et al. Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. *Psychopharmacology (Berl).* 2005;178:1–8.
- Risby ED, Hsiao JK, Golden RN, et al. Intravenous alprazolam challenge in normal subjects—biochemical, cardiovascular, and behavioral effects. *Psychopharmacology (Berl).* 1989;99:508–514.
- Charney DS, Breier A, Jatlow PI, et al. Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine. *Psychopharmacology (Berl).* 1986;88:133–140.
- Laakmann G, Wittmann M, Gugath M, et al. Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. *Psychopharmacology (Berl).* 1984;84:66–70.
- Pomara N, Willoughby LM, Ritchie JC, et al. Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. *Neuropsychopharmacology.* 2004;29:605–611.
- Holsboer F, Liebl R, Hofschuster E. Repeated dexamethasone suppression test during depressive illness—normalization of test result compared with clinical improvement. *J Affect Disord.* 1982;4:93–101.
- Christensen P, Lolk A, Gram LF, et al. Benzodiazepine-induced sedation and cortisol suppression—a placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. *Psychopharmacology (Berl).* 1992;106:511–516.
- Gram LF, Christensen L, Kristensen CB, et al. Suppression of plasma-cortisol after oral administration of oxazepam in man. *Br J Clin Pharmacol.* 1984;17:176–178.
- Gram LF, Christensen P. Benzodiazepine suppression of cortisol secretion—a measure of anxiolytic activity. *Pharmacopsychiatry.* 1986;19:19–22.
- Longo LP, Johnson B. Addiction: Part I. Benzodiazepines—side effects, abuse risk and alternatives. *Am Fam Physician.* 2000;61:2121–2128.
- Rickels K, Schweizer E, Csanalosi I, et al. Long-term treatment of anxiety and risk of withdrawal—prospective comparison of clorazepate and buspirone. *Arch Gen Psychiatry.* 1988;45:444–450.
- Cowley DS, RoyByrne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder—effects of chronic alprazolam treatment. *Neuropsychopharmacology.* 1995;12:147–157.
- Penninx BWJH, Beekman ATF, Smit JH, et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *International Journal of Methods in Psychiatric Research.* 2008;17:121–140.
- WHO Collaborating Centre for Drug Statistics Methodology: ATC/DDD System [WHO Web site]. November 23, 2009. Available at: <http://www.whocc.no/atcddd/>. Accessed November 23, 2009.
- Zitman FG, Couvee JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group. *Br J Psychiatry.* 2001;178:317–324.
- Zitman FG. Discontinueringsstrategieën. In: Kahn RS, Zitman FG, eds. *Farmacotherapie in de psychiatrie*. Maarsse: Elsevier/Bunge; 1999:165–177.
- Oude Voshaar RC, Mol AJ, Gorgels WJ, et al. Cross-validation, predictive validity, and time course of the Benzodiazepine Dependence Self-Report Questionnaire in a benzodiazepine discontinuation trial. *Compr Psychiatry.* 2003;44:247–255.
- Kan CC, Breteler MHM, Timmermans EAY, et al. Scalability, reliability, and validity of the Benzodiazepine Dependence Self-Report Questionnaire in outpatient benzodiazepine users. *Compr Psychiatry.* 1999;40:283–291.
- Kan CC, Breteler MHM, van der Ven AHGS, et al. Cross-validation of the Benzodiazepine Dependence Self-Report Questionnaire in outpatient benzodiazepine users. *Compr Psychiatry.* 2001;42:433–439.
- Vreeburg SA, Hoogendijk WJG, van Pelt J, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity results from a large cohort study. *Arch Gen Psychiatry.* 2009;66:617–626.
- van Aken MO, Romijn JA, Miltenburg JA, et al. Automated measurement of salivary cortisol. *Clin Chem.* 2003;49:1408–1409.
- Pruessner JC, Kirschbaum C, Meinlschmid G, et al. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. *Psychoneuroendocrinology.* 2003;28:916–931.

31. Bhattacharyya MR, Molloy GJ, Steptoe A. Depression is associated with flatter cortisol rhythms in patients with coronary artery disease. *J Psychosom Res.* 2008;65:107–113.
32. Vreeburg SA, Kruijtz BP, van Pelt J, et al. Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. *Psychoneuroendocrinology.* 2009;34:1109–1120.
33. Gueorguieva R, Krystal JH. Move over ANOVA—progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry. *Arch Gen Psychiatry.* 2004;61:310–317.
34. Arvat E, Maccagno B, Ramunni J, et al. The inhibitory effect of alprazolam, a benzodiazepine, overrides the stimulatory effect of metyrapone-induced lack of negative cortisol feedback on corticotroph secretion in humans. *J Clin Endocrinol Metab.* 1999; 84:2611–2615.
35. Breier A, Davis O, Buchanan R, et al. Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. *Biol Psychiatry.* 1992;32:880–890.
36. Desouza EB. Neuroendocrine effects of benzodiazepines. *J Psychiatr Res.* 1990;24:111–119.
37. Schuckit MA, Hauger R, Klein JL. Adrenocorticotropin hormone response to diazepam in healthy young men. *Biol Psychiatry.* 1992;31:661–669.
38. Voshaar RCO, Verkes RJ, van Luijcklaar GLJM, et al. Effects of additional oxazepam in long-term users of oxazepam. *J Clin Psychopharmacol.* 2005;25:42–50.
39. Mikkelsen JD, Bundzikova J, Larsen MH, et al. GABA regulates the rat hypothalamic-pituitary-adrenocortical axis via different GABA-A receptor alpha subtypes. *Ann N Y Acad Sci.* 2008; 1148:384–392.
40. de Kloet ER, Vreugdenhil E, Oitzl MS, et al. Brain corticosteroid receptor balance in health and disease. *Endocr Rev.* 1998;19:269–301.
41. Grottoli S, Giordano R, Maccagno B, et al. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. *J Clin Endocrinol Metab.* 2002;87: 4616–4620.